HDAC inhibitors not only exhibit anti-angiogenic properties across various cancer types but also enhance leukocyte adherence and movement within tumor vessels, primarily through the upregulation of ICAM-1 [86], underscoring their potential to boost the effectiveness of immunotherapy. This evidence concerns the gene ICAM1 and neoplasm.